Introduction. Intrathecal drug delivery systems (IDDSs) have dramatically improved analgesia and the functional status of cancer patients and those with chronic pain states. However, given the close proximity to the neuraxis and frequent concomitant use of antiplatelet or anticoagulant medications, this intervention is not without risk. The goal of this investigation was to determine the incidence of bleeding complications following IDDS placement.
Introduction
Pain is one of the most commonly experienced and feared symptoms faced by patients with a serious illness [1] . Despite recognition that pain is a critical part of the evaluation of a patient facing a serious illness, many patients still experience poor pain control. Among cancer patients, fully one-third experience inadequate analgesia, and many more experience unacceptable side effects [2] . With aggressive pharmacologic pain control strategies and the assistance of pain medicine and/or palliative care clinicians, most patients can achieve appropriate levels of analgesia. Literature suggests that a minority of patients with pain from a serious illness may have inadequate analgesia and/or intolerable side effects with systemic modalities. For these patients, minimally invasive interventional pain therapies can be significantly beneficial [3] . A significant number of cancer patients presenting for intrathecal drug delivery system placement are likely to be anticoagulated or receiving antiplatelet therapy.
Cancer alone is associated with a 4.1-fold risk of thrombosis, and in patients receiving chemotherapy that risk is increased 6.5-fold [4] . Placement of an intrathecal drug delivery system is a high-risk procedure, necessitating the cessation of anticoagulation in an attempt to obviate the risk of neuraxial bleeding [5, 6] . It is well established that patients with cancer have an increased risk of thrombosis [4] and also an increased risk of periprocedural bleeding [7, 8] . In addition to the likelihood of these patients being anticoagulated for a history of venous thromboembolism, there is an increased risk of bleeding due to multiple other contributing factors, including cancer and chemotherapy-related hepatic and renal dysfunction, as well as thrombocytopenia. Further, the risk of anticoagulant-induced bleeding seems to be higher in patients with cancer [9] , potentially increasing the urgency to reverse anticoagulation or withhold antiplatelet therapy in these patients prior to performance of a neuraxial procedure.
The goal of this investigation was to assess the rate of bleeding and bleeding-related neurologic complications in a large cohort of patients undergoing IDDS placement and, specifically, to focus on the use of antiplatelet and anticoagulant medications perioperatively, as well as examine the risk of bleeding complications in the presence of baseline abnormalities in the hemostatic system.
Methods
This is a retrospective study approved by the Mayo Clinic (Rochester, MN, USA) Institutional Review Board. Inclusion criteria for the investigation were age 18 years or older undergoing IDDS implantation or revision by the pain medicine division at a single tertiary care medical center between January 1, 2005, and December 31, 2014. Exclusion criteria included procedure cancellation prior to needle placement or the absence of research consent.
The primary outcome for this investigation was the presence of a neurologic complication requiring emergency medicine, neurology, or neurosurgical evaluation within 31 days of the procedure. Identified complications were independently analyzed (NSW, MAW) for their potential relationship to procedural bleeding and classified as definitely related, possibly related, or unlikely related. The secondary outcome for this investigation was the presence or absence of periprocedural red blood cell (RBC) transfusion. To qualify, the transfusion was required to occur during the procedural encounter or within 72 hours following completion of the procedure. The presence and timing of all periprocedural transfusion episodes were extracted from the electronic health record. Detailed chart review was performed for all patients with qualifying RBC transfusion episodes by two independent reviewers (NSW, MAW) to assess the cause of the transfusion episode and its relationship to procedural bleeding.
Identification of study participants was performed using the Perioperative Data Mart, an institutional resource that captures clinical and procedural data for all patients who are admitted to an acute care environment including procedural suites, operating rooms, intensive care units, and progressive care units at the study's participating institution [10] . Moreover, it contains details on patient demographics and clinical characteristics, fluid and transfusion therapies, periprocedural medications and laboratory values, and postprocedural outcomes. Aspirin or NSAID use within seven days of the procedure was defined by electronic documentation of medication administration in this preprocedural window or the absence of preprocedural discontinuation documented in the medical record. Although recent guidelines identify six days as the minimum discontinuation interval for aspirin therapy prior to high-risk interventional pain procedures [6] , this time frame was extended by one day in an attempt to be more representative of the widely accepted clinical practice of aspirin discontinuation at least seven days before high-risk surgical or interventional procedures. Additional baseline patient characteristics were extracted from a second validated database, the Mayo Clinic Life Sciences System (MCLSS) [11] . Both databases have undergone extensive validation with accuracy superior to manual data collection alone [12] .
Statistical Analysis
Baseline demographics, clinical characteristics, medications, laboratory values, and procedural information were summarized and presented as median with 25% to 75% interquartile range (IQR) for continuous data elements and frequencies (%) for categorical data, respectively. Baseline laboratory values were considered valid if obtained within 30 days of the procedure. An international normalized ratio (INR) of 1.5 or higher was used as a threshold for coagulopathy, and a platelet count lower than 100 x 10 9 /L was used as a cutoff for thrombocytopenia. The frequency of outcomes was to be assessed using point estimates with 95% confidence intervals (CIs).
Results
A total of 247 procedures were performed on 216 unique patients, including 198 IDDS implantations and 49 revisions. Of the revision procedures, 30 (61.2%) required spinal access for catheter revision or systemic replacement while 19 (38.8%) were pump exchanges. Baseline clinical, demographic, and laboratory parameters are shown in Table 1 . Patients had received aspirin or NSAIDs within seven days of needle placement for 64 procedures (25.9%). Among these, 41 patients (16.6%) received aspirin, 31 patients (12.6%) received NSAIDs, and eight patients (3.2%) had concomitant use of both aspirin and NSAIDs (Table 2) . Aspirin was present for 37 implantations (18.7%) and four revisions (8.2%, 3 with spinal access), while NSAIDs were present for 27 implantations (13.6%) and four revisions (8.2%, all with spinal access).
The median (interquartile range) time for aspirin discontinuation was three (0-6) days. Among these 41 patients, aspirin was discontinued within one day of the procedure for six (14.6%) patients, within three days for Bleeding and Intrathecal Drug Delivery Systems four (9.8%) patients, within four days for three (7.3%) patients, within five days for three (7.3%) patients, within six days for seven (17.0%) patients, and within seven days for four (9.8%) patients. Aspirin doses ranged from 81 mg to 325 mg daily, with the most common dose being 81 mg (75.6%) followed by 325 mg (22.0%).
Of the 31 patients receiving NSAIDs within seven days of the procedure, ibuprofen was the most commonly encountered drug (18/31, 58.1%). It was continued through the operative encounter for 16 of the 18 procedures (88.9%). Two patients discontinued ibuprofen, doing so one and three days before the procedure. Of the 13 procedures associated with non-ibuprofen NSAID use, therapy was continued through the operative encounter in 10 cases (76.9%). In the three procedures associated with NSAID discontinuation, the termination interval before the procedure was greater than five halflives in only one case. Of the eight patients taking concomitant aspirin and NSAID therapy, ibuprofen was utilized in four cases (50.0%), while the other four patients received diclofenac, ketoprofen, naproxen, or ketorolac. Aspirin doses were 81 mg in six cases (75%) and 325 mg in two cases (25%).
A platelet count and INR were available within 30 days of the procedure for 138 patients (55.9%). Two patients had a platelet count lower than 100 x 10 9 /L at the time of needle placement. Of these, one had a platelet count of 57 x 10 9 /L and was transfused one unit of platelets four hours before the procedure, with a recheck platelet count of 72 x 10 9 /L measured immediately before procedure initiation. The other patient had a platelet count of 58 x 10 9 /L measured two hours before the procedure and was not transfused with platelets. One patient (0.4%) had an INR of 1.5 at the time of the procedure and did not receive specific treatment for this abnormality. The cause of the patient's INR abnormality was deemed secondary to liver metastases from primary colon adenocarcinoma.
One neurologic complication was identified in this cohort (0.4%, 95% confidence interval [CI] ¼ À0.4% to 1.2%). In this case, the neurologic complication was progressive spinal cord compression 72 hours after the procedure, which prompted evaluation by magnetic resonance image (MRI). This revealed new metastatic lesions to the vertebral bodies at levels of C7 through T2. The complication was deemed to be unlikely related to procedural bleeding.
Three patients (1.2%, 95% CI ¼ À0.2% to 2.6%) received a periprocedural red blood cell transfusion within 72 hours of the procedure (Table 3) . Of these, two patients had received aspirin (81 mg) within seven days of the procedure and one had received perioperative ibuprofen therapy. There were no abnormalities in baseline platelet counts or INR values. However, all three patients had significant baseline anemia. Each of the RBC transfusion episodes was determined to be unlikely related to procedural bleeding. Two patients experienced a minimal drop in hemoglobin prior to RBC transfusion. The third patient had a preprocedural hemoglobin value of 9.3 g/dl and a pretransfusion hemoglobin value of 7.5 g/dl measured 34 hours later. This hemoglobin drop was mostly dilutional in the setting of five liters of fluid positivity (including intravenous and oral intake) during that time frame. There was no clinical mention of concern for bleeding and the patient's hemoglobin improved and stabilized after RBC transfusion.
Discussion
Recent guidelines developed specifically to assist pain medicine providers in determining the proper management of anticoagulation in the periprocedural setting have allocated IDDS implantation to the high bleeding risk category [6] . Associated with this designation is the recommendation that anticoagulant and antiplatelet medications-including aspirin and NSAIDs-should be routinely discontinued and baseline coagulation parameters normalized prior to IDDS placement. For those receiving aspirin for primary prophylaxis, a discontinuation period of at least six days is recommended. When aspirin is given for secondary prevention of additional thrombotic events (i.e., myocardial infarction, stroke), the decision to discontinue therapy should be a shared decision between the patient, the pain interventionist, and the physician prescribing aspirin. When the risk of bleeding outweighs the risk of discontinuation, aspirin should be discontinued for six days. For NSAIDs, the recommendation is to discontinue therapy for at least five half-lives prior to the procedure, a length of time that varies between one and 10 days based upon the particular NSAID.
Without a doubt, these recommendations place the prospective patient at the lowest risk of perioperative bleeding and may theoretically diminish the risk of a bleeding-related neurologic complication postoperatively. However, candidates for IDDS implantation are often patients suffering from malignancy-related pain in the setting of complex medical situations including disease or medication-related coagulation abnormalities. On occasion, it may not be feasible or medically advisable to completely eliminate anticoagulant or antiplatelet therapy preoperatively-this may be particularly true in the setting of aspirin therapy for secondary prevention of thromboembolic events. In these patients, the benefits of IDDS placement for improved analgesia in severe pain states may warrant perioperative continuation of antithrombotic therapy for the prevention of recurrent myocardial or cerebrovascular ischemia while accepting the small risk of a hemorrhagic complication, which may or may not be increased by the presence of aspirin therapy.
The primary aim of this retrospective cohort study of patients undergoing implantation of an IDDS prior to the release of the new periprocedural guidelines was to assess the rate of periprocedural bleeding-related complications, with a particular emphasis on antiplatelet medication use. To that end, not a single episode of clinically significant hemorrhage or bleeding-related neurological complication was identified. A proportion of the cohort (25.9%) was maintained on either aspirin or NSAID therapy within seven days of needle placement, and the majority of these would be considered noncompliant with recent guidelines for the discontinuation of antiplatelet therapy [6] . In this data set, there was no statistically identifiable increased risk between patients exposed to these medications and those who were not. While numbers are limited, in patients who have clear risk of thrombosis or medical necessity to continue aspirin (i.e., secondary prevention), it may be reasonable in select instances to proceed with IDDS placement. This may diminish, or at the least decrease, the risk of thrombosis due to unnecessary discontinuation of medically indicated antithrombotic therapy. Indeed, discontinuation of aspirin in patients with prior cerebrovascular events may increase the risk of recurrent stroke or transient ischemic attack by 40% [13] . Similarly, premature discontinuation of aspirin after coronary stenting has been associated with increased risk of in-stent thrombosis, recurrent myocardial infarction, and stroke [14] . In the case of prior coronary events specifically, one could argue the necessity of awaiting the completion of the appropriately designated safe interval prior to aspirin discontinuation and then proceeding with IDDS placement. While IDDS placement is an elective pain procedure, the luxury of time may not be available to those with advanced malignancy. In addition, aspirin therapy may be recommended indefinitely in many patients with prior cerebrovascular events. In these situations, the small and theoretical risk of increased bleeding events with ongoing antiplatelet therapy is likely outweighed by the risk of thrombosis with medication discontinuation. Regarding IDDS placement in patients without increased risk of thrombosis (i.e., primary prevention), discontinuation of aspirin and NSAID medications likely remains the best strategy given the known antiplatelet effects of these medications.
It is also recommended that coagulation parameters including coagulation screening tests (e.g., INR) and platelet counts be normalized prior to the placement of an IDDS. From our investigation, it remains difficult to comment on the level of thrombocytopenia or INR abnormality in which an IDDS case could be safely performed with minimal increased risk of bleeding. Only two patients in this investigation had a platelet count lower than 100 x 10 9 /L at the time of needle placement, which is likely a reflection of our hesitancy to perform these procedures in patients with thrombocytopenia. Similarly, only one patient had an INR value of 1.5 or greater. There were no bleeding or neurological complications in these patients. However, it must be recognized that coagulation abnormalities are commonly encountered in those with malignancy. For example, thrombocytopenia may be found in as few as 5% to nearly 100% of patients depending on the platelet count threshold used for defining thrombocytopenia and the underlying malignancy, with solid tumors often having relatively lower incidence and hematologic malignancies having higher incidence of thrombocytopenia [15] . Additionally, platelet quantity is not synonymous with adequate platelet function, especially in the setting of advanced malignancy. Thrombocytopenia may be a simple manifestation of the disease process itself (e.g., bone marrow failure with hypoproliferative thrombocytopenia), a marker of a worsening clinical state (e.g., disseminated intravascular coagulation, micropathic angiopathy), or the result of chemotherapy or radiation therapy. Hence, careful collaboration and discussion with the patient and his/her primary hematologist or oncologist must be undertaken before deciding the appropriate course of action for these patients. While transfusion therapy may seem an obvious answer prior to IDDS placement, not all patients will respond predictably to transfusion therapies [3, 16] . In addition, this treatment option may be associated with substantial risk, including a host of transfusion-related adverse reactions, which may be significantly detrimental or even fatal to the patient with advanced malignancy. For patients with a terminal diagnosis, accepting the increased risk of procedural bleeding may be reasonable when balanced against the benefit of increased pain control and improved quality of life. Oftentimes, these patients present with a small window for IDDS therapy to be instituted due to ongoing treatments, declining health status, or disease progression. There can be no simple answer in such cases, and a full informed consent is critical.
This study has limitations, most notably the retrospective study design. A prospective model would allow for more accurate characterization of the risks and outcomes between patients with preoperative aspirin and NSAID therapy and those without. This would also allow for the assessment of thrombotic complications associated with periprocedural antithrombotic discontinuation in addition to providing an improved assessment of bleeding complications. Furthermore, although this study contained a relatively large cohort of patients spanning a decade, the number of cases evaluated was not sufficiently powered to assess differences between those with normal preoperative coagulation parameters and those without. Most importantly, it must be recognized that bleeding-related complications are exceedingly rare in IDDS implantation, and therefore prospective trials for this outcome would be difficult to successfully implement. A well-designed multisite prospective registry would allow for a more detailed examination of the issues addressed here. However, this will likely be challenging to cultivate given the national release of anticoagulation and antiplatelet guidelines and the hesitancy to perform these high-risk procedures while the patient is on any form of antithrombotic therapy.
In summary, we aimed to provide an analysis of a 10-year cohort of patients undergoing IDDS placement with careful examination of coagulation parameters and perioperative medication therapy. We did not find an increased risk of periprocedural bleeding complications in the presence of aspirin or NSAID therapy. While this certainly does not represent an endorsement for universal continuation of antithrombotic therapy, in select cases in which the risks associated with aspirin discontinuation may be heightened (e.g., secondary prevention), it may be reasonable to proceed with the intervention after thorough evaluation of risks and benefits and a fully informed discussion with all involved stakeholders including the patient, his/her surrogates, and additional medical specialists directing the patient's care. Similarly, in the case of abnormalities in the coagulation system including elevated INR values or low platelet counts, careful clinical evaluation and close collaboration with other providers is necessary in assessing individualized risk and benefit ratios in patients with advanced cancer pain.
